| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Sophoricoside is an isoflavone glycoside that modulates mast cell-mediated allergic inflammation. It inhibits PMACI-induced histamine production and reduces pro-inflammatory cytokine levels including TNF-α, IL-8, and IL-6. It also inhibits nuclear Rel/p65 translocation and caspase-1 activity in a dose-dependent manner. Additionally, it decreases hepatic cholesterol and triglyceride levels.
|
|---|---|
| ln Vitro |
Sophoricoside is an isoflavone glycoside derived from Sophora japonica flowers and possesses anti-inflammatory, anti-cancer and immunosuppressive actions. The results showed that sophorin (50 μM) greatly decreased PMACI-induced histamine production. The inhibition rate is as high as 30.24%. The maximal inhibitory rates of sophorin (50 μM) on TNF-α, IL-8, and IL-6 were approximately 31.42%, 43.43%, and 34.24%, respectively. The inhibitory rate of sophorin (50 μM) on nuclear Rel/p65 is around 50.14%. The results demonstrated that sophorin greatly inhibited the rise in caspase-1 activity generated by PMACI in a dose-dependent manner [1].
Sophoricoside (50 μM) greatly decreases PMACI-induced histamine production with an inhibition rate as high as 30.24%. It inhibits TNF-α, IL-8, and IL-6 with maximal inhibition rates of approximately 31.42%, 43.43%, and 34.24%, respectively. The compound inhibits nuclear Rel/p65 translocation (~50.14%) and caspase-1 activity in a dose-dependent manner. |
| ln Vivo |
By taking sophoraside orally one hour prior to injecting compound 48/80, scratching behavior was decreased. Approximately 41.21% is the inhibition rate of sophorin (2 mg/kg). Scratching behavior can be reduced by 47.31% when sophorin is taken orally. An considerable recovery of atopic dermatitis occurred in mice treated with sophorin for two weeks [1].
Oral administration of sophoricoside (2 mg/kg) one hour prior to compound 48/80 injection reduces scratching behavior by approximately 41.21%. At higher oral doses, scratching behavior inhibition reaches 47.31%. In mice with atopic dermatitis, two weeks of sophoricoside treatment resulted in considerable recovery of skin lesions. At 80 and 160 mg/kg, it decreases hepatic cholesterol, triglyceride, serum LDL, and apolipoprotein B levels in a fructose-induced liver injury mouse model. |
| Enzyme Assay |
For mast cell degranulation assays, PMACI (phorbol 12-myristate 13-acetate plus calcium ionophore A23187)-stimulated mast cells are treated with sophoricoside (50 μM). Histamine release is measured by ELISA or fluorometric methods. Cytokine levels (TNF-α, IL-6, IL-8) are quantified by ELISA from cell culture supernatants. NF-κB activation is assessed by nuclear Rel/p65 translocation via Western blot or immunofluorescence.
|
| Cell Assay |
Cellular assays are performed using mast cell lines (e.g., RBL-2H3 or primary mast cells) stimulated with PMACI. Cells are pre-incubated with sophoricoside at various concentrations (typically 50 μM) before stimulation. Histamine release is measured from supernatants, and intracellular cytokine expression is analyzed by flow cytometry or qPCR. Caspase-1 activity is determined using fluorogenic substrates.
|
| Animal Protocol |
In mouse models of allergic inflammation, sophoricoside is administered orally (typically 2 mg/kg or higher) one hour prior to compound 48/80 injection. Scratching behavior is monitored and quantified over a defined period. For atopic dermatitis models, mice are treated orally with sophoricoside for two weeks, and skin lesion severity is scored. In fructose-induced liver injury models, sophoricoside (80–160 mg/kg) is administered to evaluate lipid-lowering effects.
|
| ADME/Pharmacokinetics |
As a natural isoflavone glycoside, sophoricoside is orally bioavailable. The glucoside moiety is likely hydrolyzed in the intestine to release the genistein aglycone, which is absorbed and metabolized through phase II conjugation pathways. Systemic exposure and tissue distribution are consistent with other dietary isoflavones.
|
| Toxicity/Toxicokinetics |
Sophoricoside has demonstrated a favorable safety profile in animal studies at doses up to 160 mg/kg. In vitro studies at 50 μM showed no significant cytotoxicity in mast cell assays. The compound is derived from a dietary source (Sophora japonica) and is generally considered safe for research applications.
|
| References | |
| Additional Infomation |
Sophoricoside is an isoflavone compound and a apical ketone. It has been reported to exist in Astragalus falcatum, Astragalus henryi, and other organisms with relevant data.
Sophoricoside is an isoflavone glycoside (genistein-4'-O-β-D-glucoside) with anti-inflammatory, anti-cancer, and immunosuppressive effects. It has ameliorative effects on mast cell-mediated allergic inflammation and shows potential for treating allergic inflammation diseases, as well as regulating lipogenesis and glucose metabolism. |
| Molecular Formula |
C21H20O10
|
|---|---|
| Molecular Weight |
432.3775
|
| Exact Mass |
432.105
|
| CAS # |
152-95-4
|
| PubChem CID |
5321398
|
| Appearance |
White to light brown solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
763.3±60.0 °C at 760 mmHg
|
| Melting Point |
285ºC
|
| Flash Point |
271.5±26.4 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.717
|
| LogP |
0.31
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
675
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
ISQRJFLLIDGZEP-CMWLGVBASA-N
|
| InChi Code |
InChI=1S/C21H20O10/c22-7-15-18(26)19(27)20(28)21(31-15)30-11-3-1-9(2-4-11)12-8-29-14-6-10(23)5-13(24)16(14)17(12)25/h1-6,8,15,18-24,26-28H,7H2/t15-,18-,19+,20-,21-/m1/s1
|
| Chemical Name |
5,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~96.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (4.81 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL | |
| 5 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL | |
| 10 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
